Plozasiran Wins UK Authorization for Adults With Familial Chylomicronaemia Syndrome
The MHRA has authorised plozasiran (Redemplo) for adults with familial chylomicronaemia syndrome, giving clinicians a new option for a disorder defined by extreme triglyceride excess and recurrent pancreatic injury. The approval is paired with a low-fat diet, which remains central to care because the disease itself is driven by impaired clearance of triglyceride-rich particles rather than a transient metabolic flare.
FCS is rare, but its complications are not subtle. Persistent chylomicron accumulation can precipitate acute pancreatitis, a painful inflammatory event that can escalate quickly and recur if lipid burden stays high. In practice, that makes triglyceride lowering more than a laboratory goal; it is a direct attempt to reduce the risk of pancreatic inflammation and the severe abdominal pain that often brings patients to urgent care or hospital.
Plozasiran acts by blocking production of apolipoprotein C3, a liver-made protein that slows fat breakdown. Removing that brake on lipid processing offers a biologically plausible route to lower circulating triglycerides in a condition where standard dietary restriction alone may be insufficient. The medicine is administered as a 25 mg subcutaneous injection once every three months, and patients or caregivers can give it after training, an administration pattern that may matter in a rare disease population that often needs long-term treatment outside specialist centers.
Triglyceride Reductions Were Marked Over 10 Months
The authorization rests on a main study of 75 adults with FCS. All participants followed a controlled diet, while 50 received plozasiran and 25 received placebo. After 10 months, the median triglyceride reduction reached around 80% in the plozasiran group, compared with 17% in the placebo group. In a syndrome where triglycerides can remain dangerously elevated despite dietary discipline, that degree of separation is clinically meaningful.
One sentence captures the therapeutic signal: triglycerides fell sharply when apoC3 production was suppressed.
The study also recorded fewer episodes of acute pancreatitis among participants receiving plozasiran. The release does not provide a count of events or a formal statistical analysis, so the precise magnitude of protection cannot be quantified here. Even so, the direction of effect is consistent with the underlying pathophysiology: when chylomicron clearance improves, pancreatic exposure to extreme lipid loads should fall, and the risk of inflammatory attacks should move with it.
Julian Beach, executive director of operations at the MHRA, framed the decision as an additional treatment option for adults with a rare condition that can cause serious and painful complications. He also pointed to the clinical trial data showing substantial triglyceride reduction when plozasiran was used alongside a controlled diet. The regulator will continue to monitor safety, a standard step after authorization but especially relevant when a therapy is introduced into a small, genetically defined population.
Safety Profile Centers on Glycaemia, Headache, and Injection-Site Reactions
The most common adverse effect associated with plozasiran is hyperglycaemia, which may affect more than one in 10 people. Other common effects, affecting up to one in 10 people, include headache, nausea, and reactions at the injection site. For clinicians, the glycaemic signal deserves careful attention because a drug aimed at lipid metabolism can still have metabolic consequences that require monitoring, particularly in patients already vulnerable to cardiometabolic risk.
The injection-site reactions are unsurprising for a self-administered subcutaneous medicine, but they remain relevant when treatment is spaced every three months. A long dosing interval may improve adherence, yet it also places more responsibility on training, follow-up, and patient understanding of when to seek help if adverse effects develop. Patients who suspect a side effect are advised to contact a doctor, pharmacist, or nurse and report it through the Yellow Card scheme or the MHRA Yellow Card app.
The regulatory pathway also gives useful context. The marketing authorisation was granted on 19 October 2026 to Arrowhead Pharmaceuticals Ireland Limited and approved through the International Recognition Procedure, Route B, with the European Medicines Agency serving as the reference regulator. Those details matter because they place the UK decision within a broader regulatory framework, while the final product information is still due to appear on the MHRA Products website.
Rare-Disease Management Gets a New Lipid-Lowering Tool
For adults living with FCS, the practical significance of this approval lies in the combination of potency and convenience. A quarterly injection that produces an approximately 80% median triglyceride reduction, alongside controlled dietary intake, offers a different management model from therapies that demand daily dosing or provide only modest metabolic change. In a disease where the pancreas can be injured repeatedly by the same biochemical defect, the size of the lipid response is not an abstract endpoint; it is the mechanism through which the clinical course may change.
The approval does not answer every question. The trial was small, with 75 adults, and the release does not supply longer-term outcome data beyond 10 months, detailed pancreatitis event counts, or subgroup analyses. Safety monitoring therefore remains central, particularly around hyperglycaemia, and future experience will need to clarify how durable the triglyceride reduction remains in routine care, how patients tolerate repeated quarterly dosing, and how much pancreatitis prevention can be demonstrated over longer follow-up. For now, the UK has added a new apoC3-targeting option to the limited arsenal for a rare and potentially destructive lipid disorder.